Vivaldi Biosciences Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vivaldi Biosciences's estimated annual revenue is currently $1.9M per year.(i)
  • Vivaldi Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Vivaldi Biosciences has 12 Employees.(i)
  • Vivaldi Biosciences grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.2M453-1%N/AN/A
#4
$1.6M10-66%N/AN/A
#5
$3.7M24-8%N/AN/A
#6
$2.9M3728%N/AN/A
#7
$3.1M2025%N/AN/A
#8
$2.5M16-20%N/AN/A
#9
$9.1M590%N/AN/A
#10
$4.2M27-7%N/AN/A
Add Company

Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldi's DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$1.9M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vivaldi Biosciences's People

NameTitleEmail/Phone
1
CEO, DirectorReveal Email/Phone
2
Associate ScientistReveal Email/Phone
3
Finance AdministratorReveal Email/Phone
4
CSO, Managing DirectorReveal Email/Phone
5
SVP, ManufacturingReveal Email/Phone
6
VP, Research & DevelopmentReveal Email/Phone
7
VP, Marketing & CommunicationsReveal Email/Phone
Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M12N/AN/A
#2
$1M12N/AN/A
#3
$1M12-20%N/A
#4
$0.8M130%$1.4M
#5
$0.6M1318%$9.5M